You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
SBC: BIOVINC, LLC Topic: NIDCRDESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
"Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics
SBC: DFUSION INC. Topic: 999DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel therapies for inherited muscle diseases
SBC: Medosome Biotec, LLC Topic: NIAMSDESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Deriving Bone Density from Thoracic CT Scans
SBC: BDI, Inc. Topic: NIAMSPROJECT SUMMARY ABSTRACT As people age they steadily lose bone mass and their bones become fragile and increasingly prone to hip and other fractures and this can prove fatal The American College of Radiology therefore recommends that assessment of bone mineral density BMD be performed in post menopausal women and all people over the age of every two years If indicated preventive measure ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development
SBC: QRKANSWER LLC Topic: NCIDESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes
SBC: BIONIKS Topic: NIAMSDESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.
SBC: Acumen Pharmaceuticals, Inc Topic: NIAIn the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide inhibitors for neuroinflammation and neurodegeneration
SBC: PROVAIDYA Topic: NIADESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health